Introduction
Hepatic ischemia/reperfusion (I/R) injury is a major clinical complication in liver transplantation and complex hepatic surgeries. This condition arises when blood flow is temporarily restricted (ischemia) and then restored (reperfusion), triggering oxidative stress, severe inflammation, and cell death. While the roles of proteins and microRNAs in this process are well-documented, the regulatory influence of long noncoding RNAs (lncRNAs)—transcripts longer than 200 nucleotides that do not code for proteins—remains largely unexplored. This study identifies the lncRNA expression profile in mouse livers following I/R and investigates the therapeutic potential of silencing the specific lncRNA AK139328.
Methods
The researchers utilized a mouse model involving 70% partial hepatic ischemia for 60 minutes, followed by 6 hours of reperfusion. LncRNA expression was mapped using the Arraystar Mouse LncRNA Microarray v2.0, with results validated by quantitative PCR (qPCR). To determine the functional role of AK139328, siRNA-mediated knockdown was performed in vivo via tail-vein injection three days prior to the I/R procedure. Liver damage was assessed through plasma enzyme levels (ALT/AST), histological analysis (H&E staining), and Western blotting to monitor survival signaling (Akt pathway) and inflammatory markers (NF-κB pathway).
Results
The LncRNA Landscape of I/R Injury
Microarray profiling identified 98 significantly deregulated lncRNAs in I/R-treated livers, with 71 upregulated and 27 downregulated. AK139328 emerged as a key candidate due to its high expression in normal liver and its sharp increase following injury. Located intergenically on chromosome 2, AK139328 appears to function as a distinct regulatory unit.
AK139328 Silencing Protects Against Liver Damage
Silencing AK139328 via siRNA significantly reduced biochemical markers of liver injury. Plasma ALT and AST activities were reduced by approximately 50% in the knockdown group compared to the control I/R group.
Histological examination corroborated these findings, showing markedly smaller areas of necrosis in mice where AK139328 was silenced.
Modulation of Survival and Inflammatory Signaling
The study found that AK139328 acts as a molecular bridge between survival and death pathways. Silencing the lncRNA activated the protective Akt signaling pathway, increasing levels of phosphorylated Akt (pAkt), GSK3 (pGSK3), and eNOS (peNOS). Simultaneously, knockdown inhibited the pro-inflammatory NF-κB pathway, leading to a significant decrease in inflammatory cytokines (TNF-α, MCP-1, IP-10) and reduced macrophage infiltration.
Discussion
These findings demonstrate that deregulated lncRNAs are central to the pathophysiology of liver I/R injury. AK139328, in particular, exacerbates injury by suppressing survival signals and promoting inflammation. Silencing this lncRNA offers a potent protective effect, suggesting it could be a novel target for diagnosis and treatment in clinical settings such as liver surgery or transplantation. Future research is required to define the exact biochemical interactions of AK139328 and to develop effective clinical delivery systems for lncRNA-targeted therapies.
Summary updated